Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-11 02:12 | 2026-02-06 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Officer | SELL | $29.04 | 5,000 | $145,219 | 740,188 |
| 2026-02-11 00:49 | 2026-02-09 | ZVRA | ZEVRA THERAPEUTICS, INC. | McFarlane Neil F. | Director, Officer | OPT+S | $8.56 | 14,625 | $125,186 | 387,225 |
| 2026-02-10 16:59 | 2026-02-09 | SNDX | Syndax Pharmaceuticals Inc | Goldan Keith A. | Officer | SELL | $21.03 | 3,410 | $71,705 | 140,429 |
| 2026-02-10 17:00 | 2026-02-09 | SNDX | Syndax Pharmaceuticals Inc | Metzger Michael A | Director, Officer | SELL | $21.03 | 17,159 | $360,819 | 491,690 |
| 2026-02-10 00:01 | 2026-02-09 | MRK | Merck & Co., Inc. | Zachary Jennifer | Officer | OPT+S | $119.15 | 121,573 | $14,485,690 | 68,916 |
| 2026-02-10 00:04 | 2026-02-09 | MRK | Merck & Co., Inc. | Guindo Chirfi | Officer | SELL | $118.41 | 10,000 | $1,184,101 | 70,615 |
| 2026-02-10 00:10 | 2026-02-06 | COCP | Cocrystal Pharma, Inc. | FROST PHILLIP MD ET AL | Director, 10% owner | BUY | $0.95 | 50,000 | $47,280 | 1,888,551 |
| 2026-02-10 00:25 | 2026-02-06 | GALT | GALECTIN THERAPEUTICS INC | ELDRED KARY | Director | BUY | $2.70 | 300 | $810 | 65,682 |
| 2026-02-10 00:15 | 2026-02-05 | PAHC | PHIBRO ANIMAL HEALTH CORP | BENDHEIM JACK | Director, Officer, 10% owner | SELL | $48.38 | 110,842 | $5,362,104 | 122,958 |
| 2026-02-10 05:09 | 2026-02-06 | SPRO | Spero Therapeutics, Inc. | Keutzer Timothy | Officer | SELL | $2.36 | 18,652 | $44,019 | 742,506 |
| 2026-02-10 05:31 | 2026-02-06 | SPRO | Spero Therapeutics, Inc. | Rajavelu Esther | Officer | SELL | $2.36 | 87,917 | $207,484 | 1,012,091 |
| 2026-02-10 03:47 | 2026-02-09 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | Officer | SELL | $16.66 | 14,261 | $237,618 | 42,749 |
| 2026-02-10 02:28 | 2026-02-04 | MANE | Veradermics, Inc | SUVRETTA CAPITAL MANAGEMENT, LLC | Director, 10% owner | BUY | $37.30 | 282,674 | $10,542,468 | 520,453 |
| 2026-02-07 00:18 | 2026-02-04 | MRK | Merck & Co., Inc. | Smart Dalton E. III | Officer | OPT+S | $119.68 | 6,400 | $765,920 | 8,205 |
| 2026-02-07 00:15 | 2026-02-06 | MRK | Merck & Co., Inc. | Oosthuizen Johannes Jacobus | Officer | SELL | $121.87 | 15,000 | $1,827,992 | 21,197 |
| 2026-02-07 00:13 | 2026-02-04 | MRK | Merck & Co., Inc. | Litchfield Caroline | Officer | OPT+S | $119.61 | 41,997 | $5,023,312 | 90,192 |
| 2026-02-07 00:12 | 2026-02-04 | MRK | Merck & Co., Inc. | Li Dean Y | Officer | OPT+S | $118.77 | 15,087 | $1,791,824 | 102,270 |
| 2026-02-07 00:20 | 2026-02-06 | MRK | Merck & Co., Inc. | Williams David Michael | Officer | OPT+S | $121.91 | 5,000 | $609,525 | 30,838 |
| 2026-02-06 16:04 | 2026-02-04 | ABT | Abbott Laboratories | STARKS DANIEL J | Director | BUY | $108.73 | 10,000 | $1,087,331 | 6,738,817 |
| 2026-02-07 00:10 | 2026-02-05 | MRK | Merck & Co., Inc. | Guindo Chirfi | Officer | SELL | $121.88 | 20,000 | $2,437,676 | 80,615 |
| 2026-02-07 00:57 | 2026-02-04 | ONC | BeOne Medicines Ltd. | Lee Chan Henry | Officer | OPT+S | $349.52 | 1,660 | $580,197 | 0 |
| 2026-02-07 02:38 | 2026-02-04 | RYTM | RHYTHM PHARMACEUTICALS, INC. | Smith Hunter C | Officer | SELL | $106.03 | 6,628 | $702,744 | 125,537 |
| 2026-02-07 00:08 | 2026-02-06 | MRK | Merck & Co., Inc. | DeLuca Richard R. | Officer | SELL | $120.92 | 37,685 | $4,557,025 | 160,174 |
| 2026-02-07 01:54 | 2026-02-06 | SNDX | Syndax Pharmaceuticals Inc | Metzger Michael A | Director, Officer | SELL | $20.62 | 7,412 | $152,835 | 508,849 |
| 2026-02-07 01:53 | 2026-02-06 | SNDX | Syndax Pharmaceuticals Inc | Goldan Keith A. | Officer | SELL | $20.62 | 2,082 | $42,931 | 143,839 |
| 2026-02-07 00:38 | 2026-02-06 | PTGX | Protagonist Therapeutics, Inc | Waddill William D. | Director | OPT+S | $83.68 | 20,000 | $1,673,600 | 7,825 |
| 2026-02-07 00:05 | 2026-02-04 | MRK | Merck & Co., Inc. | Davis Robert M | Director, Officer | SELL | $118.04 | 47,434 | $5,599,328 | 443,602 |
| 2026-02-07 00:18 | 2026-02-05 | INSM | INSMED Inc | Flammer Martina M.D. | Officer | SELL | $152.44 | 869 | $132,470 | 83,243 |
| 2026-02-06 00:24 | 2026-02-03 | CTNM | Contineum Therapeutics, Inc. | Lorrain Daniel S. | Officer | SELL | $14.94 | 4,170 | $62,306 | 156,052 |
| 2026-02-06 03:03 | 2026-02-05 | MANE | Veradermics, Inc | Longitude Capital Partners V, LLC | 10% owner | BUY | $17.00 | 1,075,000 | $18,275,000 | 2,053,474 |
| 2026-02-05 18:18 | 2026-02-03 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% owner | SELL | $4.10 | 5,559 | $22,792 | 550,000 |
| 2026-02-06 03:04 | 2026-02-05 | MANE | Veradermics, Inc | Coric Vlad | Director | BUY | $17.00 | 117,646 | $1,999,982 | 319,398 |
| 2026-02-05 14:30 | 2026-02-02 | SPRO | Spero Therapeutics, Inc. | Keutzer Timothy | Officer | SELL | $2.17 | 46,586 | $101,175 | 761,158 |
| 2026-02-06 00:10 | 2026-02-04 | VSTM | Verastem, Inc. | Paterson Dan | Director, Officer | SELL | $6.69 | 970 | $6,489 | 612,919 |
| 2026-02-06 00:05 | 2026-02-04 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | Officer | SELL | $32.19 | 1,745 | $56,168 | 111,226 |
| 2026-02-06 00:05 | 2026-02-04 | TVTX | Travere Therapeutics, Inc. | Inrig Jula | Officer | SELL | $32.21 | 1,779 | $57,295 | 105,706 |
| 2026-02-06 03:00 | 2026-02-03 | PMN | ProMIS Neurosciences Inc. | ABG Management Ltd. | 10% owner | BUY | $12.13 | 700,741 | $8,499,988 | 943,090 |
| 2026-02-06 00:05 | 2026-02-04 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | Officer | SELL | $32.18 | 2,994 | $96,359 | 105,211 |
| 2026-02-06 03:03 | 2026-02-05 | MANE | Veradermics, Inc | ENRIGHT PATRICK G | Director, 10% owner | BUY | $17.00 | 1,075,000 | $18,275,000 | 2,053,474 |
| 2026-02-06 01:42 | 2026-02-03 | CORT | CORCEPT THERAPEUTICS INC | Guyer William | Officer | OPT+S | $40.87 | 20,000 | $817,334 | 1,235 |
| 2026-02-06 00:31 | 2026-02-05 | UTHR | UNITED THERAPEUTICS Corp | MAHON PAUL A | Officer | OPT+S | $483.25 | 8,300 | $4,010,939 | 36,781 |
| 2026-02-06 03:22 | 2026-02-03 | PAHC | PHIBRO ANIMAL HEALTH CORP | BENDHEIM JACK | Director, Officer, 10% owner | SELL | $41.39 | 13,180 | $545,473 | 48,800 |
| 2026-02-06 04:17 | 2026-02-05 | CYTK | CYTOKINETICS INC | Callos Andrew | Officer | OPT+S | $61.93 | 15,000 | $928,950 | 50,440 |
| 2026-02-06 03:04 | 2026-02-05 | MANE | Veradermics, Inc | CHILDS JOHN W | Director | BUY | $17.00 | 294,117 | $4,999,989 | 2,202,006 |
| 2026-02-05 04:02 | 2026-02-03 | TNGX | Tango Therapeutics, Inc. | Crystal Adam | Officer | SELL | $12.26 | 18,452 | $226,301 | 187,218 |
| 2026-02-05 01:07 | 2026-02-02 | RPRX | Royalty Pharma plc | Coyne Terrance P. | Officer | SELL | $42.54 | 243,541 | $10,360,819 | 22,885 |
| 2026-02-05 04:09 | 2026-02-03 | TNGX | Tango Therapeutics, Inc. | Weber Barbara | Director, Officer | SELL | $12.26 | 30,519 | $374,294 | 1,629,254 |
| 2026-02-05 04:35 | 2026-02-02 | ARQT | Arcutis Biotherapeutics Inc. | Matsuda Masaru | Officer | SELL | $25.28 | 40,638 | $1,027,292 | 110,003 |
| 2026-02-05 03:25 | 2026-02-02 | ARQT | Arcutis Biotherapeutics Inc. | Watanabe Todd | Director, Officer | SELL | $25.50 | 19,833 | $505,710 | 721,306 |
| 2026-02-05 03:24 | 2026-02-02 | ARQT | Arcutis Biotherapeutics Inc. | Vairavan Latha | Officer | SELL | $25.50 | 1,320 | $33,658 | 63,607 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.